Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

AI – Opportunities and Challenges in Transforming the Biopharma Value Chain


Published on

These slides were presented by Pamela Spence, EY Global Life Sciences Industry Leader, at the annual BIO International Convention on 20 June 2017. Pamela led a panel discussion on Artificial Intelligence (AI) and the opportunities and challenges it presents in transforming the biopharma value chain. The panelists included Dr. Attul Butte, Director of the Institute for Computational Health Science at the University of California – San Francisco, Iya Khalil, Chief Commercial Officer and Co-founder of GNS Healthcare, Nathan Price, Associate Director of the Institute for Systems Biology and co-founder of Arivale, and Jackie Hunter, CEO of Benevolent AI

Published in: Business
  • Login to see the comments

  • Be the first to like this

AI – Opportunities and Challenges in Transforming the Biopharma Value Chain

  1. 1. AI – Opportunities and Challenges in Transforming the Biopharma Value Chain Pamela Spence, EY Global Life Sciences Industry Leader BIO 2017 San Diego
  2. 2. Artificial intelligence. Evolution, revolution or destruction?
  3. 3. >90% of the world’s data has been created in the last two years Data was … “just” connecting of created data is used 0.5% Data is … moving to “real-time” collaboration Data future … “interrogating for value”
  4. 4. 38% of enterprises use some sort of AI of those who don’t cite lack of clarity regarding its value proposition 20% Source: Narrative Science – Outlook on AI in the Enterprise 2016 Data was … “just” connecting Data is … moving to “real-time” collaboration Data future … “interrogating for value”
  5. 5. So what is intelligence?
  6. 6. Technology advancement is linear Human intelligence - complex, flexible, multiple domains Narrow intelligence now in machines. Superhuman processing speeds. Building systems of atoms that display more intelligent behavior will eventually build general intelligence into our machines Thinking cognitive machines – an inevitability
  7. 7. Can the power of machines replace human insight? How can we keep ourselves safe in these exciting times … utopia, not a dystopia? Is access to a data set really a problem? How do we get all stakeholders to trust machines and embrace the inevitable “new normal”?
  8. 8. Title (Arial bold 30 point) Subtitle (Arial regular 20 point) XX Month 200X (Arial regular 16 point) How can we collaborate with machines to meet health care’s unmet needs?
  9. 9. EY | Assurance | Tax | Transactions | Advisory About EY EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities. EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit How EY’s Global Life Sciences Sector can help your business As populations age and chronic diseases become commonplace, health care will take an ever larger share of GDP. Scientific progress, augmented intelligence and a more empowered patient are driving changes in the delivery of health care to a personalized experience that demands health outcomes as the core metric. This is causing a power shift among traditional stakeholder groups, with new entrants (often not driven by profit) disrupting incumbents. Innovation, productivity and access to patients remain the industry’s biggest challenges. These trends challenge the capital strategy of every link in the life sciences value chain, from R&D and product supply to product launch and patient-centric operating models. Our Global Life Sciences Sector brings together a worldwide network of 15,000 sector-focused professionals to anticipate trends, identify their implications and help our clients create competitive advantage. We can help you navigate your way forward and achieve sustainable success in the new health- outcomes-driven ecosystem © 2017 EY GM Limited All Rights Reserved. EYG No. 04127-174Gbl 1706-2332246 ED None This material has been prepared for general informational purposes only and is not intended to be relied upon as accounting, tax or other professional advice. Please refer to your advisors for specific advice. .